"The Food and Drug Administration on Friday approved the first pill for postpartum depression, a milestone considered likely to increase recognition and treatment of a debilitating condition that afflicts about a half-million women in the United States every year."
https://www.nytimes.com/2023/08/04/health/postpartum-depression-pill-fda.html?action=click&module=Well&pgtype=Homepage&section=Health

In April I wrote about how this new class of drugs were developed for #NatureMedicine. Read it at the link below:

https://www.nature.com/articles/d41591-023-00032-8

#ScienceCommunication #DrugDevelopment #PostPartum #scicomm

Effects of urban living environments on #MentalHealth are studied by the EU network environMENTAL led by #CharitéBerlin. In #NatureMedicine, the team analyzes how environmental factors may contribute to #depression, #anxiety, or #stress

👉 https://www.charite.de/en/research/engl_neues_aus_der_forschung/2023/from_the_source_new_findings_on_effects_of_urban_living_environments_on_mental_health/

#CharitéNeuro #CharitéPaper #ScienceMastodon #Science #Research

Einflüsse städtischen Lebens auf die psychische Gesundheit studiert der EU-Verbund environMENTAL unter Leitung der #CharitéBerlin. In #NatureMedicine analysiert das Team, wie Umweltfaktoren zu #Depressionen, #Angst oder #Stress beitragen.

👉 https://www.charite.de/forschung/paper_spotlight/2023/neue_erkenntnisse_zum_einfluss_des_urbanen_umfeldes_auf_die_psychische_gesundheit/

#CharitéNeuro #CharitéPaper #Forschung #Wissenschaft

🌟 Exciting research suggests that bee venom contains components that may have potential against breast cancer. 🐝💪

Read the full article on the Rapusia.org blog to learn more about this promising discovery and its implications for cancer treatment. Let's continue to explore nature's incredible resources for our well-being! 🌿🌼

https://blog.rapusia.org/health/2197/bee-venom-would-have-components-against-breast-cancer/

#RapusiaOrg #HealthNews #BeeVenom #BreastCancerResearch #NatureMedicine 🌟🐝💪

Gene therapy with AAV vectored micro-dystrophin for Duchenne muscular dystrophy. My latest #ClinicalPipeline column for #NatureMedicine.

#drugdevelopment #SciComm #MuscularDystrophy #Pharma

https://www.nature.com/articles/d41591-023-00052-4

I wrote about RSV vaccines in my #NatureMedicine column in February.
Very good news this week with the FDA approval of GSK's RSV vaccine for adults 60 and over - it's the first approved RSV vaccine.

https://edition.cnn.com/2023/05/03/health/first-rsv-vaccine-approved/index.html

Several other candidate RSV vaccines are at a late stage of development, including mRNA based vaccines. The next big thing to watch for are those seeking to protect newborns and infants by maternal immunisation.

#RSV #Vaccine #RespiratoryVirus #drugdevelopment #Pharma #Immunology

https://www.nature.com/articles/d41591-023-00017-7

The FDA has approved Biogen's ALS drug, Tofersen, an antisense oligo targeting SOD1. I wrote about this back in September in my Clinical Pipeline column as part of a shift towards approving drugs based on biomarkers without clear signs of clinical efficacy*.

https://www.nature.com/articles/d41591-022-00098-w

*You can have a look at the trial data in NEJM, in a study that concluded that "In persons with SOD1 ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events."

https://lnkd.in/dwGMYGgh

#NatureMedicine #amyotrophiclateralsclerosis #drugdevelopment #pharma

My latest Clinical Pipeline column for #NatureMedicine, on fitusiran, a small interfering RNA for the treatment of hemophilia A or B. It may be particularly useful for patients with inhibitors (antibodies against clotting factors).

#drugdevelopment #drugdiscovery #SciComm #sciencecommunication #pharma #hemophilia 👇

https://www.nature.com/articles/d41591-023-00037-3

"On 2 February 2022, President Joe Biden announced new efforts to extend the Cancer Moonshot1 to address bold but achievable new goals: to reduce cancer mortality by at least 50% in the next 25 years and improve the experience of people and their families living with and surviving cancer."

#Cancer #CancerResearch #NatureMedicine

https://www.nature.com/articles/s41591-022-01881-5

The topic of my latest #NatureMedicine Clinical Pipeline column, zuranolone, represents an improvement in both safety & ease of administration over its on its predecessor, brexanolone (which was the first drug approved specifically for postpartum depression in 2019). The case for it in major depressive disorder is more complex.

https://www.nature.com/articles/d41591-023-00032-8

My latest Clinical Pipeline column for #NatureMedicine is a look at zuranolone, a new antidepressant developed by Sage & Biogen, targeting the GABA pathway.

#drugdiscovery #drugdevelopment #depression #GABA #neuroscience

https://www.nature.com/articles/d41591-023-00032-8

My latest Clinical Pipeline column for #NatureMedicine is now online. A new take on heart failure using iPSC derived cardiomyocytes.

#drugdevelopment #cardiology #stemcells #regeneration

https://www.nature.com/articles/d41591-023-00027-5

My latest Clinical Pipeline column for #NatureMedicine is now online. A new take on heart failure using iPSC derived cardiomyocytes.

#drugdevelopment #cardiology #stemcells #regeneration

'Using two independent real-world datasets from three different countries and an independent validation cohort based on the global, double-blind, placebo-controlled, phase 3 RECOURSE trial, we demonstrate that codon-specific KRAS mutations predict OS benefit for patients treated with the chemotherapeutic agent FTD/TPI in late-stage mCRC.'

#NatureMedicine #KRAS #PrecisionMedicine

https://www.nature.com/articles/s41591-023-02240-8#Sec7

Interesting piece in Nature about the type 1 #diabetes drug Teplizumab, the first that the FDA has ever approved to delay the onset of the disease:

https://www.nature.com/articles/d41586-023-00400-x?utm_source=linkedin&utm_medium=social&utm_content=organic&utm_campaign=CONR_JRNLS_AWA1_GL_SCON_SMEDA_NATUREPORTFOLIO#ref-CR11

I wrote about the drug in mid December for #NatureMedicine

https://www.nature.com/articles/d41591-022-00115-y

#HIV patient #cured after bone marrow transplant in rare case

A man in Germany who had been diagnosed w/HIV has been declared free of the virus after receiving HIV-resistant stem cells through a bone marrow transplant intended to treat leukemia. Acc/to research published in the journal #NatureMedicine on Mon, the man was monitored for >9 yrs after the 2013 transplant, & there is now “strong evidence” that he has been cured.

https://www.washingtonpost.com/health/2023/02/21/duesseldorf-patient-hiv-cured-stem-cell/

My latest Clinical Pipeline column for #NatureMedicine is out, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.
#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-023-00017-7

My latest Clinical Pipeline column for #NatureMedicine is out today, a look at Moderna's RNA vaccine for RSV & a survey of what's, well, in the pipeline, for RSV immunotherapies, including vaccines and monoclonals.

#Vaccine #drugdiscovery #drugdevelopment #mRNA #RSV #immunology #MonoclonalAntibody

https://www.nature.com/articles/d41591-023-00017-7

Sagy et al. have recently published in #NatureMedicine an analysis of the real-world efficacy of #JYNNEOS, the #smallpox shot redeployed against #monkeypox.
https://www.nature.com/articles/s41591-023-02229-3

Last Fall I wrote a column for Nature Medicine that touched on the FDA's Animal Rule, used in the approval of anti-smallpox drugs due to the difficulty in designing ethically acceptable efficacy screens.

https://www.nature.com/articles/d41591-022-00094-0

"Despite the growing number of regulatory approvals for use of these drugs in a number of different malignancies, it is now becoming clear that many patients who receive ICIs do not benefit from treatment but remain at risk for potentially serious immune-related adverse events. Expanding the benefit of ICIs to more patients and limiting the impact of their adverse effects will require better biomarkers of response and toxicity."

#Immunology #Immunotherapy #NatureMedicine

https://www.nature.com/articles/s41591-022-02154-x